A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors (NCT06157892)
A Phase 1b/2 Open-Label Study of Disitamab Vedotin in Combination With Other Anticancer Therapies in Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
This clinical trial is studying solid tumor cancers. A solid tumor is one that starts in part of your body like your lungs or liver instead of your blood. Once they've grown bigger in one spot or spread to other parts of the body, they're harder to treat. This is called advanced or metastatic cancer. Participants in this study must have breast cancer or gastric cancer. Participants must have tumors that have HER2 on them. This allows the cancer to grow more quickly or spread faster. There are few treatment options for patients with advanced or metastatic solid tumors that express HER2. This clinical trial uses an experimental drug called disitamab vedotin (DV). Disitamab vedotin is a type of antibody drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. This clinical trial uses a drug called tucatinib, which has been approved to treat cancer in the United States and some other countries. This drug is sold under the brand name TUKYSA®. This study will test how safe and how well DV with tucatinib works for participants with solid tumors. This study will also test what side effects happen when participants take these drugs. A side effect is anything a drug does to the body besides treating the disease.
Who can join: Review the eligibility criteria below.
Location: Banner-University Medical Center Tucson Campus — Tucson, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (135 Sites)
Showing the first 25 of 135 sites.
- Banner-University Medical Center Tucson Campus — Tucson, Arizona
- Banner-University Medical Center Tucson Campus — Tucson, Arizona
- The University of Arizona Cancer Center-North Campus Pharmacy, Attn: Kelly Myrdal — Tucson, Arizona
- University of Arizona Cancer Center - North Campus — Tucson, Arizona
- The University of Arizona Cancer Center-Main — Tucson, Arizona
- UC Irvine Health - Chao Family Comprehensive Cancer Center — Orange, California
- UC Irvine Medical Center — Orange, California
- University of California, San Francisco | HDFCCC - Hematopoietic Malignancies — San Francisco, California
- UCLA Department of Medicine - Hematology & Oncology — Santa Monica, California
- UCLA Hematology/Oncology - Parkside — Santa Monica, California
- Colorado West Healthcare System, dba Community Hospital — Grand Junction, Colorado
- Colorado West Healthcare, dba Grand Valley Oncology — Grand Junction, Colorado
- Georgetown University Medical Center — Washington D.C., District of Columbia
- MedStar Georgetown University Hospital — Washington D.C., District of Columbia
- Moffitt Cancer Center - International Plaza — Tampa, Florida
- H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida
- Moffitt Cancer Center - McKinley Campus — Tampa, Florida
- Moffitt McKinley Hospital — Tampa, Florida
- Moffitt Cancer Center at Wesley Chapel — Wesley Chapel, Florida
- Georgia Cancer Specialists - Athens — Athens, Georgia
- Georgia Cancer Specialists - Annex — Atlanta, Georgia
- Atlanta Cancer Care - Atlanta — Atlanta, Georgia
- Georgia Cancer Specialists-Northside — Atlanta, Georgia
- Northside Hospital, Inc.- Central Research Department — Atlanta, Georgia
- Northside Hospital — Atlanta, Georgia
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Breast Neoplasms
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) — Birmingham, Alabama
- (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer — Phoenix, Arizona
- Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer — Dallas, Texas
- Assessment of Quality of Life and Treatment Times for Patients With Invasive Type Breast Cancer in Martinique — Fort-de-France,
- Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer — Springdale, Arkansas
- The IDEA Study (Individualized Decisions for Endocrine Therapy Alone) — Stanford, California
Explore by condition: All Breast Neoplasms clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.